References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.47360/1995-4484-2022-165-173

rsp-3149

Research Article

МЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙ

INTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASES

Обзор рекомендаций American College of Rheumatology / Vasculitis Foundation по лечению системных васкулитов крупных сосудов (гигантоклеточного артериита и артериита Такаясу)

Review of guideline for the management of large vessel vasculitis presented in 2021 by the American College of Rheumatology / Vasculitis Foundation

https://orcid.org/0000-0003-2641-9785

Бекетова

Т. В.

Beketova

T. V.

Татьяна Валентиновна Бекетова

115522, Москва, Каширское шоссе, 34а; 107023, Москва, ул. Большая Семёновская, 384; 121359, Москва, ул. Маршала Тимошенко, 15

Tatiana V. Beketova

115522, Moscow, Kashirskoye Highway, 34A; 121359, Moscow, Marshala Timoshenko str., 15; 107023, Moscow, B. Semyenovskaya St, 38

tvbek@rambler.ru

https://orcid.org/0000-0002-6373-332X

Попов

И. Ю.

Popov

I. Yu.

115522, Москва, Каширское шоссе, 34а

Ivan Yu. Popov

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-7064-5301

Зеленов

В. А.

Zelenov

V. A.

115522, Москва, Каширское шоссе, 34а

Vasiliy A. Zelenov

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГБУ Центральная клиническая больница с поликлиникой Управления делами Президента РФ; ФГАОУ ВО Московский политехнический университет РоссияРоссияV.A. Nasonova Research Institute of Rheumatology; Central Clinical Hospital of the Administrative Directorate of the President of the Russian Federation; Moscow Polytechnic UniversityRussian Federation

ФГБНУ Научноисследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2022

14052022

602165173

2022

Бекетова Т.В., Попов И.Ю., Зеленов В.А.

Beketova T.V., Popov I.Y., Zelenov V.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/3149

Обсуждаются основные положения рекомендаций Американской коллегии ревматологов (American College of Rheumatology) и Фонда васкулитов (Vasculitis Foundation) по лечению пациентов с системными васкулитами крупных сосудов, которые были опубликованы в августе 2021 г. В результате подробного рассмотрения современных данных группой экспертов были предложены 22 рекомендации и 2 дополнения для гигантоклеточного артериита (ГКА), а также 20 рекомендаций и 1 дополнение для артериита Такаясу (АТ), на основании которых представлены алгоритмы лечения пациентов с данными заболеваниями. Зафиксировано расширение значения генно-инженерной биологической терапии, в первую очередь тоцилизумаба при ГКА и ингибиторов фактора некроза опухоли альфа при АТ. Новые рекомендации не должны рассматриваться как окончательные стандарты, но призваны стать основанием для выбора персонифицированной стратегии лечения больных с васкулитами крупных сосудов и послужить отправной точкой для дальнейших исследований.

The main statements of the recommendations of the American College of Rheumatology and the Vasculitis Foundation on the treatment of patients with systemic vasculitis of large vessels, published in August 2021, are discussed. As a result of a detailed review of current data, a group of experts proposed 22 recommendations and 2 ungraded position statements for giant cell arteritis (GCA), as well as 20 recommendations and 1 ungraded position statement for Takayasu arteritis (AT), on the basis of which algorithms for the treatment of patients with these diseases are presented. An expansion of the value of genetically engineered biological therapy, primarily tocilizumab in GCA and tumour necrosis factor alpha inhibitors in AT, has been recorded. The new recommendations should not be considered as final standards, but are intended to become the basis for choosing a personalized treatment strategy for patients with large vessels vasculitis and serve as a starting point for further research.

системный васкулит крупных сосудовгигантоклеточный артериитартериит Такаясулечениебиологическая терапия

large vessel vasculitisgiant cell arteritisTakayasu arteritistocilizumabtumour necrosis factor α inhibitors

Исследование не имело спонсорской поддержки

References1

Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. doi: 10.1002/art.41774

Chung SA, Gorelik M, Langford CA, Maz M, Abril A, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol. 2021;73(8):1384-1393. doi: 10.1002/art.41776

Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi: 10.1002/art.41773

Бекетова ТВ, Попов ИЮ, Бабак ВВ. Обзор рекомендаций по лечению АНЦА-ассоциированных системных васкулитов, представленных в 2021 г. Американской коллегией ревматологов и Фондом васкулитов. Научно-практическая ревматология. 2021;59(6):684-692. doi: 10.47360/1995-4484-2021-684-692

Beketova TV, Popov IYu, Babak VV. Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/ Vasculitis Foundation. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):684-692 (In Russ.). doi: 10.47360/1995-4484-2021-684-692

Mahr A, Saba M, Kambouchner M, Polivka M, Baudrimont M, Brochériou I, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65(6):826-828. doi: 10.1136/ard.2005.042770

Durling B, Toren A, Patel V, Gilberg S, Weis E, Jordan D. Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis. Can J Ophthalmol. 2014;49(2):157-161. doi: 10.1016/j.jcjo.2013.12.008

Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al.; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67(10):2569-2580. doi: 10.1002/art.39333

Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120(12):987-992. doi: 10.7326/0003-4819-120-12199406150-00003

Bury D, Joseph J, Dawson TP. Does preoperative steroid treatment affect the histology in giant cell (cranial) arteritis? J Clin Pathol. 2012;65:1138-1140. doi: 10.1136/jclinpath-2012-200870

Le K, Bools LM, Lynn AB, Clancy TV, Hooks WB 3rd, Hope WW. The effect of temporal artery biopsy on the treatment of temporal arteritis. Am J Surg. 2015;209(2):338-341. doi: 10.1016/j.amjsurg.2014.07.007

Ray-Chaudhuri N, Kiné DA, Tijani SO, Parums DV, Cartlidge N, Strong NP, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002;86(5):530-532. doi: 10.1136/bjo.86.5.530

Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636-643. doi: 10.1136/annrheumdis-2017-212649

Pfadenhauer K, Weinerth J, Hrdina C. Vertebral arteries: А target for FDG-PET imaging in giant cell arteritis? Clinical, ultrasonographic and PET study in 46 patients. Nuklearmedizin. 2011; 50:28-32. doi: 10.3413/nukmed-0335-10-07

Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, et al. Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018;77(8):1165-1171. doi: 10.1136/annrheumdis-2018-213102

Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum. 2012;64(3):866-875. doi: 10.1002/art.33413

Walter MA, Melzer RA, Schindler C, Müller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32(6):674-681. doi: 10.1007/s00259-004-1757-9

Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. 18 F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439-449. doi: 10.1002/art.40379

Grayson PC, Tomasson G, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol. 2012;39(2):303-309. doi: 10.3899/jrheum.110652

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. doi: 10.1056/NEJMoa1613849

Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789-2797. doi: 10.1002/art.22754

Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al.; International Network for the Study of Systemic Vasculitides. A multicenter, randomized, doubleblind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309-1318. doi: 10.1002/art.10262

Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921-1927. doi: 10.1016/S0140-6736(16)00560-2

Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al.; Vasculitis Clinical Research Consortium. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837-845. doi: 10.1002/art.40044

Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074-2081. doi: 10.1136/annrheumdis-2013-203586

Aeschlimann FA, Eng SWM, Sheikh S, Laxer RM, Hebert D, Noone D, et al. Childhood Takayasu arteritis: Disease course and response to therapy. Arthritis Res Ther. 2017;19(1):255. doi: 10.1186/s13075-017-1452-4

Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, Lambert M, et al.; French Takayasu Network. Efficacy of biological-targeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. Circulation. 2015;132(18):16931700. doi: 10.1161/CIRCULATIONAHA.114.014321

Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term follow-up. Arthritis Care Res (Hoboken). 2012;64(7):1079-1083. doi: 10.1002/acr.21636

Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878

Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, et al.; French Takayasu Network. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. J Autoimmun. 2018;91:55-60. doi: 10.1016/j.jaut.2018.04.002

Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484-1491.

Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A doubleblind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310-3318. doi: 10.1002/art.22163

Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. J Rheumatol. 2020;47(2):255263. doi: 10.3899/jrheum.181219

Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, et al.; French Takayasu Network. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: A multicenter study of 318 patients. Circulation. 2017;136(12):1114-1122. doi: 10.1161/CIRCULATIONAHA.116.027094

Gülcü A, Gezer NS, Akar S, Akkoç N, Önen F, Göktay AY. Long-term follow-up of endovascular repair in the management of arterial stenosis caused by Takayasu’s arteritis. Ann Vasc Surg. 2017;42:93-100. doi: 10.1016/j.avsg.2016.10.066

García-Martínez A, Hernández-Rodríguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004;51:674-678. doi: 10.1002/art.20541

Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Predictors of cardiovascular hospitalization in giant cell arteritis: Effect of statin exposure. A French population-based study. J Rheumatol. 2016;43(12):2162-2170. doi: 10.3899/jrheum.151500

de Souza AW, Machado NP, Pereira VM, Arraes AE, Reis Neto ET, Mariz HA, et al. Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J. 2010;74(6):1236-1241. doi: 10.1253/circj.cj-09-0905

Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford). 2009;48(3):258-261. doi: 10.1093/rheumatology/ken480

Narváez J, Bernad B, Gómez-Vaquero C, García-Gómez C, Roig-Vilaseca D, Juanola X, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57-S62.

Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332-1337. doi: 10.1002/art.20171

Both M, Aries PM, Müller-Hülsbeck S, Jahnke T, Schäfer PJ, Gross WL, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. Ann Rheum Dis. 2006;65(9):1124-1130. doi: 10.1136/ard.2005.048470

Clifford AH, Arafat A, Idrees JJ, Roselli EE, Tan CD, Rodriguez ER, et al. Outcomes among 196 patients with noninfectious proximal aortitis. Arthritis Rheumatol. 2019;71(12):2112-2120. doi: 10.1002/art.40855

Mennander AA, Miller DV, Liang KP, Warrington KJ, Connolly HM, Schaff HV, et al. Surgical management of ascending aortic aneurysm due to non-infectious aortitis. Scand Cardiovasc J. 2008;42(6):417-424. doi: 10.1080/14017430802023086

Kinjo H, Kafa A. The results of treatment in renal artery stenosis due to Takayasu disease: Comparison between surgery, angioplasty, and stenting. A monocentrique retrospective study. G Chir. 2015;36:161-167. doi: 10.11138/gchir/2015.36.4.161

Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Postinterventional immunosuppressive treatment and vascular restenosis in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45:600-605. doi: 10.1093/rheumatology/kei245

Wang X, Dang A, Lv N, Cheng N, Cheng X, Yang Y, et al. Longterm outcomes of coronary artery bypass grafting versus percutaneous coronary intervention for Takayasu arteritis patients with coronary artery involvement. Semin Arthritis Rheum. 2017;47:247-252. doi: 10.1016/j.semarthrit.2017.03.009

Labarca C, Makol A, Crowson CS, Kermani TA, Matteson EL, Warrington KJ. Retrospective comparison of open versus endovascular procedures for Takayasu arteritis. J Rheumatol. 2016;43(2):427-432. doi: 10.3899/jrheum.150447

Khalilullah M, Tyagi S. Percutaneous transluminal angioplasty in Takayasu arteritis. Heart Vessels Suppl. 1992;7:146-153. doi: 10.1007/BF01744561

Sharma S, Gupta H, Saxena A, Kothari SS, Taneja K, Guleria S, et al. Results of renal angioplasty in nonspecific aortoarteritis (Takayasu disease). J Vasc Interv Radiol. 1998;9(3):429-435. doi: 10.1016/s1051-0443(98)70294-5

Sun Y, Ma L, Ma L, Kong X, Chen H, Lv P, et al. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu’s arteritis. Rheumatol Int. 2017;37(12):2019-2026. doi: 10.1007/s00296-017-3847-6

Zheng T, Zhu S, Ou JF, Fang WG, Qiao ZY, Qi RD, et al. Treatment with corticosteroid and/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu’s arteritis. J Invest Surg. 2019;32(3): 220-227. doi: 10.1080/08941939.2017.1408718

Fields CE, Bower TC, Cooper LT, Hoskin T, Noel AA, Panneton JM, et al. Takayasu’s arteritis: Operative results and influence of disease activity. J Vasc Surg. 2006;43(1):64-71. doi: 10.1016/j.jvs.2005.10.010

Ham SW, Kumar SR, Wang BR, Rowe VL, Weaver FA. Late outcomes of endovascular and open revascularization for nonatherosclerotic renal artery disease. Arch Surg. 2010;145(9):832-839. doi: 10.1001/archsurg.2010.183

The authors declare that there are no conflicts of interest present.